<DOC>
	<DOCNO>NCT02267434</DOCNO>
	<brief_summary>Study AFF011 randomize controlled parallel Group phase I study investigate safety tolerability two dos vaccine AFFITOPE® PD03A give patient early Parkinson 's disease . In total 36 patient enrol 3 independent group ( 2 treatment group , 1 Placebo group ) , consist 12 patient . The patient randomize either receive 15µg 75µg AFFITOPE® PD03A formulate adjuvant reference substance without active component ( Placebo ) . Over study duration 52 week , study participant receive 4 injection basic immunization 4-weekly interval 1 boost immunization 36 week first injection . Male female patient age 45 70 year participate trial . 2 study site Austria ( Innsbruck Vienna ) involve . AFF011 part project SYMPATH fund European Commission ( FP7-HEALTH-2013-INNOVATION-1 project ; N° HEALTH-F4-2013-602999 ) .</brief_summary>
	<brief_title>Study Assessing Tolerability Safety AFFITOPE® PD03A Patients With Early Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<criteria>Individuals IPS diagnose less 4 year present Hoehn &amp; Yahr Stages I/II fulfill United Kingdom Parkinson 's Disease Society Brain Bank Criteria The result DATSPECT MRI examination patient 's brain consistent diagnosis PD Written Informed Consent Form sign date patient Age 45 70 Female patient childbearing potential eligible use medically accept contraceptive method A potential participant treat conventional PD therapy must stable dos least 3 month prior Visit 0 entire trial period must stable responder Accepted PD medication include follow : levodopa ( alone combination benserazide , carbidopa ) , CatecholOmethyltransferase inhibitor ( entacapone , tolcapone ) , amantadine , nonergot dopamine agonist ( pramipexol , ropinirol , rotigotine ) , monoamine oxidaseB inhibitor ( rasagiline , selegiline ) anticholinergic medication A potential participant stable dos medication he/she take consist illness accord medical history ( except PD therapy , record separately ) least 30 day prior Visit 0 , consider relevant PI Upon PI 's opinion , visual auditory impairment would reduce patient ' ability complete study questionnaire unable receive instruction Pregnant woman Sexually active woman childbearing potential use medically accept birth control method throughout study Participation another clinical trial within 3 month Visit 0 History questionable compliance visit schedule ; patient expect complete clinical trial Presence history allergy component vaccine , consider relevant PI Contraindication MRI image metallic endoprosthesis stent implantation last 6 month allergy MRI contrast agent Contraindication DATSPECT Contraindication lumbar puncture anticoagulation Dementia History and/or presence autoimmune disease , consider relevant PI Recent ( ≤3 year since last specific treatment ) history cancer ( Exceptions : basal cell carcinoma , intraepithelial cervical neoplasia ) Active infectious disease ( e.g. , Hepatitis B , C ) Presence and/or history Immunodeficiency ( e.g. , HIV ) Significant systemic illness ( e.g. , chronic renal failure , chronic liver disease , poorly control diabetes , poorly control congestive heart failure , deficiency ) , consider relevant PI History significant psychiatric illness schizophrenia , bipolar affective disorder psychotic depression Parkinsonlike disease secondary drug therapy side effect ( e.g. , due exposure medication deplete dopamine [ reserpine , tetrabenazine ] block dopamine receptor [ neuroleptic , antiemetic ] Parkinsonplus syndrome ( e.g . MSA , PSP ) Heredodegenerative disorder Alcoholism substance abuse within past year ( alcohol drug intoxication ) Prior and/or current treatment experimental immunotherapeutics include intravenous immunoglobulin Prior and/or current treatment immunosuppressive drug Change dose standard treatment PD within 3 month prior Visit 0 Change dose previous current medication patient take consist illness accord medical history ( except PD therapy , record separately ) within last 30 day prior Visit 0 , clinically relevant Treatment deep brain stimulation Venous status render impossible place i.v . access LDopa relate motor complication ( response fluctuation and/or dyskinesia ) Evidence genetic form PD : leucinerich repeat kinase 2 Parkin</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>